The role of DPP-4 inhibitors in diabetological care


  • Polozova L. G. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine



diabetes mellitus type 2, glucose-lowering therapy, incretins, DPP-4 inhibitors, Vildagliptin, Gliptar


Diabetes mellitus type 2 is the most important medical problem in many countries within the world. The features of hypoglycemic drug with high efficiency include the effectivity, safety, usability, ability to prevent progressive deterioration of pancreatic β-cell function under long-term treatment conditions, and positive impact on the outcomes of diabetes. Inhibitors of dipeptidyl peptidase-4 (DPP-4) belong to the class of glucose reducing drugs which has proved the existence of the potential benefit for clinical diabetology in 10 years. The development of incretinomimetics led to changes in national and international recommendations for the therapy of diabetes. Vildagliptin is included to the family of DPP-4 inhibitors which is widely used in many countries among the world for more than 10 years, although it was introduced inside Ukrainian market only in September 2018 (GLIPTAR, production of Kyivmedpreparat). International clinical trials have shown the great potential of the therapy with vildagliptin which can be characterized by the effectivity either the safety, and it may be stipulated by achievement of glycemic control without complications and other side effects. The advantages of Vildagliptin mono-therapeutic strategy compared to the traditional drugs provide the opportunity to be recommended for initiating therapy of 2 type of diabetes. The validated combination of vildagliptin with other glucose-lowering drugs allows to health care specialists to comprehensively build the treatment approach for all stages of the exacerbation of type 2 diabetes therapy.


Drucker DJ. Diabetes Care 2003; 26: 2929-2940.

Wang Q, Li L, Wong V, et al. Diabetologia 2004; 47 (3): 478-487. doi:

Crash Course: Metabolism and Nutrition, 4 ed, available at:

Nathan DM, Buse JB, Davidson MB, et al. Diabetes Care 2008; 31: 1-11.

Edwards CMB, Winocour PH. Practical Diabetes Int 2009; 26 (5): 191-194.

Recommendation of the Council for Further Combating Bribery of Foreign Public Officials in International Business Transactions, available at:

ААСЕ Statement by an American Association of Clinical Endocrinologists. Endocr Pract 2009; 15 (6): 540-549.

Villhauer E, Brinkman J, Naderi G, et al. J Med Chem 2003; 46: 2774-2789.

Burkey BF, Russell M, Wang K, et al. Diabetologia 2006; 49 (1): 485-486.

El-Ouaghlidi A, Rehring E, Holst JJ, et al. J Clin Endocrinol Metab 2007; 92 (11): 4165-4171.

Schweizer A, Couturier A, Foley JE, et al. Diabet Med 2007; 24: 955-961.

Ahren B, Pacini G, Foley J, Schweizer A. Diabetes Care 2005; 28: 1936-1940.

Ferrannini E, Fonseca V, Zinman B, et al. Diabetes Obes Metab 2009; 11 (2): 157-166.

Pittas AG, Joseph NA, Greenberg AS. J Clin Endocrinol Metab 2004; 89 (2): 447-452.

Macauley M, Hollingsworth KG, Smith FE, et al. J Clin Endocrinol Metab 2015; 100 (4): 1578-1585.

Matthews DR, Dejager S, Ahren B, et al. Diabetes Obes Metab 2010; 12 (9): 780-789.

Matikainen N, Manttari S, Schweizer A, et al. Diabetologia 2006; 49 (9): 2049-2057.

Boschmann M, Engeli S, Dobberstein K, et al. J Clin Endocrinol Metab 2009; 94 (3): 846-852.

Bosi E, et al. Diabetes Care 2007; 30: 890-95.

Hirose T, Suzuki M, Tsumiyama I. Diabetes Ther 2015;6 (4): 559-571.

Schweizer A, Couturier A, Foley JE, et al. Diabet Med 2007; 24: 955-961.

Bosi E, Camisasca RP, Collober C, et al. Diabetes Care 2007; 30: 890-895.

McInnes G, Evans M, Del Prato S, et al. Diabetes Obes Metab 2015; 17 (11): 1085-1092.

Khan S, Khan S, Panda BP, et al. Expert Opin Ther Targets 2015;19(12): 1607-1616. doi:

Cosenso-Martin LN, Giollo-Junior LT, Martineli DD, et al. Diabetol Metab Syndr 2015; 26 (7): 70. doi:

Hissa MR, Cavalcante LL, Guimaraes SB, Hissa MN. Diabetol Metab Syndr 2015;11 (7): 62. doi:

Cosenso-Martin LN, Giollo-Junior LT, Vilela-Martin JF. Medicine (Baltimore) 2015;94(27): e1068. doi:

El-Sherbeeny NA, Nader MA. Can J Physiol Pharmacol 2015; 24: 1-6. doi:

Mera J, Okada E, Okuda M, et al. J Diabetes Metab Disord 2015; 14: 83. doi:

Bekiari E, Rizava C, Athanasiadou E, et al. Endocrine 2016; 52 (3): 458-80. doi:

Yang W, Cai X, Han X, Ji L. Diabetes Metab Res Rev 2016; 32 (4): 391-404. doi:

Foley J, Hoffmann P, Ligueros-Saylan M, et al. Lack of vildagliptin effects on the immune system: EASD. Poster presentation 2009: 773.

Kothny W, Schweizer A, Dickinson S, Ligueros-Saylan M. Hepatic safety profile of vildagliptin, a new DPP-4 inhibitor for the treatment of type 2 diabetes: EASD. Poster presentation 2009: 764.

Schweizer A, Dejager S, Shao Q, et al. Assessing cardiovascular safety of vildagliptin: EASD. Poster Presentation 2009: 763.

Nathan DM, Buse JB, Davidson MB, et al. Diabetes Care 2008; 31: 1-11.




How to Cite

Polozova, L. G. . (2021). The role of DPP-4 inhibitors in diabetological care. Problems of Endocrine Pathology, 66(4), 16-26.